

Annex 1

Numbers of new cases and registered deaths by age group from 2015 to 2017 of the top ten causes of cancer deaths in Hong Kong in 2017¹

Ranking ²	Cancer types	Age group (years old)	Number of new cases			Number of registered deaths		
			2015	2016	2017	2015	2016	2017
1	Lung	0-19	2	0	0	0	1	0
		20-44	111	104	140	77	52	56
		45-64	1 558	1 713	1 655	1 037	953	991
		65 or above	3 077	3 119	3 383	2 917	2 774	2 843
		Total³	4 748	4 936	5 178	4 031	3 780	3 890
2	Colorectum	0-19	3	1	0	1	2	0
		20-44	189	225	203	50	46	41
		45-64	1 753	1 892	1 820	488	514	528
		65 or above	3 091	3 319	3 612	1 534	1 527	1 569
		Total³	5 036	5 437	5 635	2 073	2 089	2 138
3	Liver	0-19	3	3	6	2	2	3
		20-44	65	73	88	43	46	40
		45-64	728	797	729	503	520	479
		65 or above	995	937	1 011	1 023	972	1 030
		Total³	1 791	1 810	1 834	1 571	1 540	1 552
4	Breast	0-19	0	0	0	0	0	0
		20-44	649	690	733	53	52	51
		45-64	2 212	2 324	2 397	362	356	402
		65 or above	1 059	1 109	1 261	222	296	270
		Total³	3 920	4 123	4 391	637	704	724
5	Pancreas	0-19	0	0	1	0	0	0
		20-44	18	18	23	13	13	10
		45-64	267	243	252	220	195	186
		65 or above	481	441	490	458	470	494
		Total³	766	702	766	691	678	690
6	Stomach	0-19	0	1	0	0	0	0
		20-44	54	43	54	27	33	22
		45-64	366	394	425	179	178	168
		65 or above	747	786	835	463	499	492
		Total³	1 167	1 224	1 314	669	710	682
7	Prostate	0-19	0	0	0	0	0	0
		20-44	2	1	0	0	0	0
		45-64	414	416	529	20	38	29
		65 or above	1 415	1 495	1 711	384	372	414
		Total³	1 831	1 912	2 240	404	410	443
8	Non-Hodgkin lymphoma	0-19	12	20	20	3	1	3
		20-44	113	105	98	16	14	18
		45-64	372	372	387	97	76	87
		65 or above	479	466	497	242	297	286
		Total³	976	963	1 002	358	388	395
9	Leukaemia	0-19	65	59	54	7	9	7
		20-44	89	94	77	38	28	27
		45-64	173	174	210	77	84	69
		65 or above	233	225	258	219	188	211
		Total³	560	552	599	341	309	314

Ranking ²	Cancer types	Age group (years old)	Number of new cases			Number of registered deaths		
			2015	2016	2017	2015	2016	2017
10	Oesophagus	0-19	0	0	0	0	0	0
		20-44	9	8	4	5	3	3
		45-64	158	170	143	98	104	103
		65 or above	259	273	249	196	228	191
		Total³	426	451	396	299	335	297

Note:

- ¹ New cases and deaths regarding various types of cancers in a year might not be contributed by the same pool of patients. Rankings for the number of registered deaths were not the same as those of new cases.
- ² Rankings were determined by the number of registered deaths in 2017.
- ³ Cases with age unknown were included.

**New drugs introduced to the coverage of the Samaritan Fund and
the Community Care Fund Medical Assistance Programmes in the past three years**

2017-18

Drug		Diseases to be treated
Samaritan Fund		
1	Canakinumab	Cryopyrin-associated periodic syndromes
2	Crizotinib	Lung cancer
3	Everolimus	For renal angiomyolipoma associated tuberous sclerosis complex, tuberous sclerosis complex with subependymal giant cell astrocytoma
Community Care Fund Medical Assistance Programmes		
1	Abiraterone	Prostate cancer
2	Enzalutamide	Prostate cancer
3	Pertuzumab	Breast cancer
4	Eculizumab	Paroxysmal Nocturnal Haemoglobinuria, Atypical haemolytic uraemic syndrome

2018-19

Drug		Diseases to be treated
Samaritan Fund		
1	Afatinib	Lung cancer
2	Alemtuzumab	Multiple sclerosis
3	Panitumumab	Colorectal cancer
4	Secukinumab	Ankylosing spondylitis, Psoriatic arthritis, Severe psoriasis
5	Tofacitinib	Rheumatoid arthritis
6	Vedolizumab	Severe ulcerative colitis
Community Care Fund Medical Assistance Programmes		
1	Alectinib	Lung cancer
2	Axitinib	Renal cell carcinoma
3	Ceritinib	Lung cancer
4	Everolimus	Breast cancer
5	Nivolumab	Skin cancer
6	Obinutuzumab	Leukaemia
7	Osimertinib	Lung cancer
8	Palbociclib	Breast cancer
9	Trastuzumab emtansine (T-DM1)	Breast cancer
10	Nusinersen	Spinal Muscular Atrophy

2019-20

Drug		Diseases to be treated
Samaritan Fund		
1	Alectinib	Lung cancer
2	Baricitinib	Rheumatoid arthritis
3	Carfilzomib	Multiple myeloma
4	Ceritinib	Lung cancer
5	Ibrutinib	Lymphoma, Leukaemia
6	Mepolizumab	Severe refractory eosinophilic asthma (add-on treatment)
7	Nintedanib	Idiopathic pulmonary fibrosis
8	Obinutuzumab	Lymphoma
9	Omalizumab	Severe persistent confirmed allergic IgE mediated asthma
10	Sarilumab	Rheumatoid arthritis
Community Care Fund Medical Assistance Programmes		
1	Dabrafenib	Skin cancer
2	Trametinib	Skin cancer
3	Ribociclib	Breast cancer
4	Tafamidis	Transthyretin amyloidosis